United States securities and exchange commission logo





                             January 10, 2022

       Marshall Fordyce, M.D.
       President, Chief Executive Officer and Director
       Vera Therapeutics, Inc.
       8000 Marina Boulevard, Suite 120
       Brisbane, CA 94005

                                                        Re: Vera Therapeutics,
Inc.
                                                            Draft Registration
Statement on Form S-1
                                                            Submitted January
4, 2022
                                                            CIK No. 0001831828

       Dear Dr. Fordyce:

                                                        This is to advise you
that we do not intend to review your registration statement.

               We request that you publicly file your registration statement no
later than 48 hours prior
       to the requested effective date and time. Please refer to Rules 460 and
461 regarding requests for
       acceleration. We remind you that the company and its management are
responsible for the
       accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
       absence of action by the staff.

                                                        Please contact Jeffrey
Gabor at 202-551-2544 with any questions.




                             Sincerely,


                             Division of Corporation Finance

                             Office of Life Sciences
       cc:                                              Alexa M. Ekman, Esq.